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Background:Optimalmanagement of patientswith persistent foramen ovale (PFO) following cryptogenic
stroke or transient ischemic attack (TIA) suspected for paradoxical embolic events is still unclear. PFO
closure has the potential beneﬁt of preventing recurrent embolic events and avoiding serious bleeding
resulting from long-term anticoagulation. Despite the widespread usage of closure devices, no ran-
domized trial supports the general percutaneous closure approach. In addition, only mid-term, but not
long-term,outcomeshavebeen reporteduntil now.Theaimof the study is toassess clinical characteristics
and long-term clinical outcome of patients undergoing percutaneous PFO closure.
Methods: Included in this single-center registry trial were 146 consecutive patients who underwent
percutaneous closure of PFO at the University Hospital Frankfurt from 2000 to 2009. Periprocedural
outcomes and long-term events were assessed. Follow-up was available in 146 patients (100%) with a
mean follow-up of 7.8±3.1 years (cumulative 1148 patient-years).
Results: The cerebroischemic event leading to indicate percutaneous PFO closure was TIA (34.9%), stroke
without sequels (38.4%), strokewith sequels (24.7%), amaurosis fugax (N=2; 1.4%), and peripheral emboli
(N=1; 0.7%). Only one severe periprocedural complication occurred (device dislocation). The majority of
patients (N=143; 97.9%) experienced no further events during follow-up.
Conclusion: This “all-comers” population documents the safety of percutaneous PFO closure. The cardio-
vascular event rate is slightly lower (0.26 per 100 patient years) compared to the recently published
randomized trials and maintained persistently low rate for more than 8 years.
© 2ntroduction
The patent foramen ovale (PFO) is an interatrial communica-
ion that persists after birth in more than 25% of the population
1]. PFO is suspected to be responsible for paradoxical emboli. But
espite the widely performed percutaneous closure for secondary
revention of cryptogenic stroke the precise role of PFO in the
athogenesis of cryptogenic strokehas not yet been establishedbut
ften remains as the only explanation [2–5]. Atrial septal defects
ASDs) are also described as rare causes of paradoxical emboli
6]. The randomized CLOSURE I trial of transcatheter PFO closure
ersus medical management did not support the maintenance of
his approach [7]. The recently reportedPC trial [8] and theRESPECT
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trial [9] also failed to showabeneﬁt of PFO closure in comparison to
permanent anticoagulation in the primary intention-to-treat anal-
ysis. However, closurewas superior tomedical therapy alone in the
prespeciﬁed per-protocol and as-treated analyses in the RESPECT
trial. But off-label device closure of PFO outside of these trials is
common, especially in subjects suspected to be at high risk for
recurrent events.
In addition, the randomized trials cover only an intermediate
follow-up period of 2 years and 4 years, respectively. A larger
registry trial was also restricted by a mean follow-up period of
approximately 3 years [10]. Little is known about a longer course
exceeding 4 years for patients who underwent percutaneous clo-
sure. Therefore, the analysis of event rates over a longer period after
PFO closure would be helpful to determine the best approach.The aim of our retrospective study was to evaluate patient
characteristics and the clinical long-term outcome of patients
undergoing percutaneous closure of PFO or ASD after a suspected
paradoxical thromboembolic event in an “all-comers” population.
llege of Cardiology.
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for the paradoxical emboli. Spontaneous right-left shunt without
provocation by Valsalva maneuver occurred in 62 patients (42.5%).
In 61 patients (41.8%), an atrial septum aneurysm was found.
Table 1
Baseline characteristics.
All patients
Mean age (years) 47.5±12.0
Age range 19–78
Male sex 79 (54.1%)
History of smoking 60 (41.1%)
Family history of cardiovascular events 52 (35.6%)
Hypertension 47 (32.2%)
Hypercholesterolemia 57 (39.0%)
Diabetes 7 (4.8%)
Index event: ﬁrst event 108 (75.0%)
Atrial ﬁbrillation 4 (2.8%)
Thrombophilia 20 (13.7%)
Table 2
Procedural indication and characteristics.
All patients
Index event
Transient ischemic attack 34.9%
Stroke without sequels 38.4%
Stroke with sequels 24.7%
Amaurosis fugax 1.4%
Peripheral emboli 0.7%
Implanted device
AMPLATZERTM PFO Occluder 91.8%
Device size (18/25/35mm) 9/82/9%14 R. Lehmann et al. / Journal
ethods
tudy population – inclusion criteria
A total of 146 consecutive patients with PFO or ASD and sus-
ected paradoxical thromboembolic event treated from January
000 to December 2009 with a PFO or ASD closure device were
ncluded in the analysis.
The implantation procedure was performed according to the
iscretion of the responsible interventionalist. Usually the patients
ere admitted to hospital one day before the procedure. PFO was
onﬁrmed by combined transesophageal and contrast echocardi-
graphy. Contrast echocardiography was performed by injection
f agitated galactose solution (Echovist, Bayer Germany) into a
ubital vein during Valsalva maneuver. The detection of contrast
icrobubbles in the left atrium within 3 cardiac cycles after con-
rast appearance in the right heart was considered positive for PFO.
inor, moderate, and severe right-to-left shunts were deﬁned as
ess than 10, more than 10, and full opaciﬁcation of the left atrium
ith microbubbles, respectively.
The closure procedure was performed under local anesthesia.
he device implantation was guided by means of ﬂuoroscopy.
dditionally, transesophageal echocardiography was used in ASD
atients. Type and size of the closure device were selected accord-
ng to the individual anatomic conditions: defect size, atrial size,
resence of an atrial septum aneurysm, and distance between
FO/ASD and aortic root.
Recommended antithrombotic treatment after the procedure
ncluded acetylsalicylic acid (100mg per day) for 6 months and
lopidogrel (75mg per day) for 3 months.
All patientswere scheduled for postprocedural transesophageal
chocardiography one or two days after the procedure and an addi-
ional evaluation 6 months later.
rocedures
Clinical data were acquired from the patients’ medical his-
ory and diagnostic test reports, including those of blood tests. All
ecordsand interventionalprotocolswere systematically reviewed.
All patients were scheduled for transesophageal echocardiogra-
hy 6 months after the procedure.
ollow-up
Clinical outcome was primarily assessed by telephone calls
patients, relatives, physicians) or through a query to the resident’s
egistration ofﬁce. We deﬁned the recurrence of new symptomatic
eurological events [transient ischemic attack (TIA), stroke, amau-
osis fugax] as the primary endpoint. Secondary endpoints were
ardiovascular death and the incidence of atrial rhythm distur-
ances. Telephone follow-up was performed between June 2011
nd June 2012. In those cases in which the required information
asnot available through telephone interviews, the local resident’s
egistration ofﬁce or the patient’s general practitioner was con-
acted instead. The lastdateonwhich thepatientwas seenalivewas
ncluded in our analysis. Follow-updatawere available in all (100%)
atients with a mean follow-up of 7.8±3.1 years (cumulative 1148
atient-years).
tatistics
Data are expressed as percentages for discrete variables and
s mean± SD for continuous variables. Continuous variables were
ompared by ANOVA and discrete parameters by exact Fisher’s
est. Statistical signiﬁcance was assumed at p<0.05. All statistical
nalyses were performed using SPSS for Windows 21.0 (Cary, NC,
SA).iology 64 (2014) 113–116
Results
Baseline characteristics
In total 146 consecutive patients were included. Baseline char-
acteristics are shown inTable1. In summary, 79 (54%)patientswere
male, 47 (32%) patients had hypertension, and 60 (41%) had a his-
tory of smoking. At least 36% (52 patients) of the study population
reported a family history of cardiovascular events. Only a minority
suffered from diabetes mellitus.
Characteristics of the index event
Thecerebroischemicevent leading to indicatepercutaneousPFO
closure was TIA in 51 patients (34.9%), stroke without sequels in 55
patients (38.4%), stroke with sequels in 36 patients (24.7%), amau-
rosis fugax in 2 patients (1.4%), and peripheral emboli in 1 patient
(0.7%; Table 2).
Further relevant comorbidities
Twenty (13.7%) patients had a proven thrombophilia. In 4
patients (2.8%) atrial ﬁbrillation was diagnosed before PFO clo-
sure. The indication for PFO closure was a contraindication of oral
anticoagulation.
Echocardiographic characteristics
In 11 (7.5%) patients, an ASD was found as the causative reasonInitial procedural result
No residual shunt 69.9%
Minor residual shunt 23.3%
Moderate residual shunt 6.2%
Severe residual shunt 0.7%
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rocedural characteristics and procedural complications
The procedural characteristics are summarized in Table 2. A
otal of 134 patients received an AMPLATZERTM PFO Occluder (St.
ude Medical, St. Paul, MN, USA), 8 patients an AMPLATZERTM
SD Occluder (St. Jude), and additional 4 patients a PFO Star
evice (Cardia, Inc, Eagan, MN, USA). In only 1 case was the pro-
edure unsuccessful due to dislocation of the device (Amplatzer
FO Occluder 18mm) and requiring cardiothoracic intervention
ith removal of the device and surgical closure of the PFO. Per-
utaneous removal was not attempted because of dislocation into
he left atrium. No procedural atrioventricular-block was detected.
ne patient developed periprocedural atrial ﬁbrillation which was
reated with cardioversion. Most important, no vascular complica-
ions at the puncture side were detected.
chocardiographic procedural results (pre-discharge and 6-month
ollow-up)
One day after PFO closure no residual shunt was detectable in
02 (69.9%) patients in the pre-discharge transesophageal echocar-
iogram. In 34 (23.3%) patients, aminor residual shuntwaspresent.
ine (6.2%) patients had moderate shunts and 1 (0.7%) patient had
severe shunt after the procedure as deﬁned by the responsible
chocardiographer.
At 6months, 77 patients (52.7%) underwent an additional trans-
sophageal echocardiography at the University Hospital Frankfurt.
f thesepatients, thedevicewas correctly positioned in all patients.
nly three patients had a detectable minor residual shunt.
ntithrombotic medication on follow-up
After PFO occluder implantation, all patients received clo-
idogrel for 3 months and aspirin for 6 months. Therapeutic
nticoagulation was terminated before the procedure generally.
our (2.7%) patients were still on clopidogrel during follow-up, 52
35.6%) patients were on aspirin, and even 3 (2.1%) patients were
till on oral anticoagulation due to atrial ﬁbrillation.
ardiovascular events during follow-up period
No patients died during follow-up. The majority of patients
N=143; 96.6%) experienced no further events during follow-up.
uring the follow-up period a new TIA occurred in one (0.7%)
atient, a stroke without sequels in an additional patient, and
maurosis fugax in one patient (Table 2). All events occurred
etween years 3 and 9 of follow-up. The speciﬁc patient charac-
eristics are depicted in Table 3.
able 3
vents during follow-up - patient characteristics.
Patient 1 60 years, female, Factor V-Leiden
Post-implant: no residual shunt (pre-discharge and 6-month
follow-up)
Index event: amaurosis fugax
Follow-up event: amaurosis fugax
Patient 2 40 years, male
Post-implant: no residual shunt (pre-discharge and 6-month
follow-up)
Index event: stroke with sequels
Follow-up event: transient ischemic attack
Patient 3 54 years, female
Post-implant: no residual shunt (pre-discharge and 6-month
follow-up)
Index event: stroke without sequels
Follow-up event: stroke without sequelsiology 64 (2014) 113–116 115
Incidence of rhythm disturbances
Rhythm disturbances with any therapeutic consequence at all
occurred in 5 (3.4%) patients. In 4 patients, paroxysmal atrial ﬁbril-
lation was detected after the procedure. One patient received a
pacemaker due to recurrent syncopes, and one additional patient
due toanatrioventricularblockﬁveyears after the indexprocedure.
In both cases, all postprocedural echocardiograms conﬁrmed per-
sistent, adequatepositionof thePFOocclusiondevice.Anadditional
six patients reported temporary palpitation mainly early after the
procedure (day 0–3) without the necessity of speciﬁc therapeutic
intervention.
Discussion
We performed a long-term follow-up over a 10-year implan-
tation period. Irrespective of the ongoing discussion about the
indication of percutaneous closure of PFO, this single-center reg-
istry study demonstrates the safety and feasibility of this approach
beyond randomized trials. In 99.3% of patients, the closure device
was successfully implanted (145 out of 146 patients). Effective clo-
sure of the PFO (no or little residual shunt) was achieved in 136
patients (93.8%). It is notable that in the available randomized trials,
the device was ﬁnally not implanted in a markedly higher propor-
tion – up to 10.6% in CLOSURE I, which might affect the results
that are based on an intention-to-treat-analysis. In addition, in all
randomized trials, cross-over in the medical group by implanta-
tion of a PFO occluder occurred out of protocol. The characteristics
of the three available randomized trials and our registry study are
summarized in Table 4.
Only onemajor complicationwasdetected: the procedure failed
due to device dislocation. More importantly, no major vascular
complication occurred. That represents a major difference to the
CLOSURE I trial, which compared treatment with a percutaneous
closure device plus antiplatelet medical treatment with medical
treatment alone in patientswith cryptogenic stroke or TIA and doc-
umentedPFO. This study showedanadverse-event rate of 16.9% [7],
including 3.2% vascular complications.
Atrial ﬁbrillation was detected in 4 (2.7%) patients after the pro-
cedure. The data interpretation is limited, because no systematic
screening by Holter-electrocardiography was performed. Similar
rates of atrial ﬁbrillation were reported in the closure group of the
PC trial and the RESPECT trial (2.9% and 3.0%, respectively). Both
studies also compared closure of a PFO with the Amplatzer PFO
Occluder with medical treatment in patients who had had a cryp-
togenic ischemic stroke. The incidence of atrial ﬁbrillation in the
medical-therapy groupswas 1.0% and 1.5% and did not differ signif-
icantly from the closure groups. In the closure group of CLOSURE I,
5.7% of patients encountered atrial ﬁbrillation suggesting a possible
impact of the different closure device types.
In this study, therewasnoevidenceofprocedure-related throm-
bus formation by transesophageal echocardiography, either at the
surface of the device or in the atria in any of the patients peri-
procedural and at 6 months follow-up. In the CLOSURE I and the
RESPECT trial, thrombus formationwas reported in 2 patients (0.5%
and 0.4%, respectively).
In the further follow-up time, the risk of additional cere-
brovascular events was low. Three cerebrovascular events in 1148
cumulative patient-years resulted in an event rate of 0.26 per 100
patient years following PFO closure in our population. Importantly,
all threeof thesepatientshadno residual shunt in thepre-discharge
transesophageal echocardiogram, which was conﬁrmed again 6
months later. These ﬁndings conﬁrm the characteristics in the CLO-
SURE I trial, in which none of the successful occluded PFO patients
who had a recurrent stroke or TIA had residual leaking on the
116 R. Lehmann et al. / Journal of Cardiology 64 (2014) 113–116
Table 4
Comparison with randomized trials (device group).
CLOSURE I RESPECT PC trial Frankfurt registry
No. of patients 447 449 204 146
Control group Yes Yes Yes No
Device StarFlex Amplatzer PFO
Occluder
Amplatzer PFO
Occluder
92.5% Amplatzer
PFO Occluder
Successful implantation 89.4% 92.6% 93.6% 99.3%
Age (years) 46.3±9.6 45.7±9.7 44.3±10.2 47.5±12.0
Male gender 52.1% 53.7% 45.1% 54.1%
Diabetes n.a. 6.6% 2.5% 4.8%
Hypertension 33.8% 31.7% 24.0% 32.2%
Index event
Stroke 72.6% 100% 80.9% 63.1%
Transient ischemic attack 27.4% 0% 16.2% 34.9%
Peripheral embolism 0% 0% 2.9% 2.0%
Atrial septum aneurysm 37.6% 36.1% 23.0% 41.8%
Preprocedural at least moderate shunt 55.9% 78.2% 70.2% 50.0%
Follow-up time 2 years
894 patient
2 years
1375 patient
ye
4 years
845 patient
7.8±3.1 years
1148 patient years
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[9] Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS,years
Events per 100 patient years 0.66
.a. = not assessed.
ransesophageal echocardiogram at 6 months. This ﬁnding raises
he question if all risk factors of recurrent strokes can really be
etected by the common work-up. Careful evaluation of patients
ith cryptogenic stroke is essential.
The overall event rate per patient-year is lower compared to
he CLOSURE I, PC, and RESPECT trials in the provided data with
xtensive follow-up period. Despite the non-direct comparable
opulations it could behypothesized that the event-rate of patients
ollowing PFO occlusion remains constantly low. It must also be
entioned that the follow-up of the randomized trials, which
nclude patients with ﬁrst cryptogenic stroke at a mean age of the
id-forties, seems in general too short to investigate a possible
eneﬁt of percutaneous PFO closure. Irrespective of the allocated
herapy (medical vs. interventional) it must be questioned when
urther events can be expected in cryptogenic stroke patients. Only
he RESPECT trial showed a potential beneﬁt of PFO closure in the
s-treated analyses. This study had the most stringent inclusion
riteria by excluding the TIA patients without proven substantial
erebral defect supporting an interventional approach in selected
igh-risk patients.
Further trials have to be designed with longer follow-up. In
ddition only experienced interventionalists should participate
n these trials in order to assure the lowest possible compli-
ation rate of the interventional group. Otherwise the potential
eneﬁt of the interventional approach can be underestimated or
ven obliterated due to elevated periprocedural complications.
he high periprocedural complication rate in the CLOSURE I trial
as attributed to the limited experience of the participating
enters.
tudy limitations
There are intrinsic limitations to the data due to the design as
retrospective non-randomized study design without a control
roup. Secondly, the echocardiographic evaluation of the patients
as not predeﬁned.We included the ﬁndings of thewritten reports
nto the analysis and did not reevaluate the video documenta-
ion. Echocardiographic evaluation might not be consistent over
he entire study period. For example, the deﬁnitions for atrial
eptal aneurysm vary widely in the literature (10- to 15-mm total
xcursion, 10 to 15mm in 1 direction or the other, etc.) and were
ot predeﬁned for this population. Echocardiographic evaluation
f a residual shunt at 6-month follow-up was only available in half
f the patients.
[ars years
39 0.82 0.26
Similar to the CLOSURE 1 but contrary to the RESPECT and PC
trial, patients with TIA as the index event were also implanted. In
addition, in the investigated population, cerebral magnetic reso-
nance imaging was not standard. Partly discrimination between
stroke and TIA was performed on cerebral computed tomography
scans or based on clinical judgment.
Conclusion
This “all-comers” population documents the long-term safety
of percutaneous PFO closure. The cardiovascular event rate is low
and remains low for 8 years. Given this excellent safety proﬁle,
PFO closure might be useful in a highly selected patient population
with elevated risk of recurrent events following cryptogenic stroke.
Further trials should be focused on such patients.
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